2500 related articles for article (PubMed ID: 25147029)
21. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions).
Gada H; Kirtane AJ; Newman W; Sanz M; Hermiller JB; Mahaffey KW; Cutlip DE; Sudhir K; Hou L; Koo K; Stone GW
JACC Cardiovasc Interv; 2013 Dec; 6(12):1263-6. PubMed ID: 24239202
[TBL] [Abstract][Full Text] [Related]
22. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
[TBL] [Abstract][Full Text] [Related]
23. Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent Versus Durable-Polymer Everolimus-Eluting Stent for Percutaneous Coronary Revascularization: 2-Year Results of the BIOSCIENCE Trial.
Zbinden R; Piccolo R; Heg D; Roffi M; Kurz DJ; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Franzone A; Eberli F; Jüni P; Windecker S; Pilgrim T
J Am Heart Assoc; 2016 Mar; 5(3):e003255. PubMed ID: 26979080
[TBL] [Abstract][Full Text] [Related]
24. Long-term comparison of sirolimus-eluting and bare-metal stents in ST-segment elevation myocardial infarction.
Wijnbergen I; Tijssen J; Brueren G; Peels K; van Dantzig JM; Veer MV; Koolen JJ; Michels R; Pijls NH
Coron Artery Dis; 2014 Aug; 25(5):378-83. PubMed ID: 24736301
[TBL] [Abstract][Full Text] [Related]
25. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
Naidu SS; Krucoff MW; Rutledge DR; Mao VW; Zhao W; Zheng Q; Wilburn O; Sudhir K; Simonton C; Hermiller JB
JACC Cardiovasc Interv; 2012 Jun; 5(6):626-35. PubMed ID: 22721657
[TBL] [Abstract][Full Text] [Related]
26. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome of the unrestricted use of everolimus-eluting stents compared to sirolimus-eluting stents and paclitaxel-eluting stents in diabetic patients: the Bern-Rotterdam diabetes cohort study.
Simsek C; Räber L; Magro M; Boersma E; Onuma Y; Stefanini GG; Zanchin T; Kalesan B; Wenaweser P; Jüni P; van Geuns RJ; van Domburg RT; Windecker S; Serruys PW
Int J Cardiol; 2013 Dec; 170(1):36-42. PubMed ID: 24196314
[TBL] [Abstract][Full Text] [Related]
28. Unrestricted use of 2 new-generation drug-eluting stents in patients with acute myocardial infarction: a propensity score-matched analysis.
Chen KY; Rha SW; Wang L; Li YJ; Li GP; Poddar KL; Park JY; Choi CU; Park CG; Seo HS; Oh DJ; Jeong MH; Ahn YK; Hong TJ; Kim YJ; Hur SH; Seong IW; Chae JK; Cho MC; Bae JH; Choi DH; Jang YS; Chae IH; Kim CJ; Yoon JH; Chung WS; Seung KB; Park SJ;
JACC Cardiovasc Interv; 2012 Sep; 5(9):936-45. PubMed ID: 22995881
[TBL] [Abstract][Full Text] [Related]
29. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
30. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.
Jensen LO; Thayssen P; Christiansen EH; Maeng M; Ravkilde J; Hansen KN; Hansen HS; Krusell L; Kaltoft A; Tilsted HH; Berencsi K; Junker A; Lassen JF;
J Am Coll Cardiol; 2016 Feb; 67(7):751-62. PubMed ID: 26892409
[TBL] [Abstract][Full Text] [Related]
31. The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS).
Wykrzykowska J; Serruys P; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Corti R; Wijns W; Morice MC; Di Mario C; Van Geuns RJ; Van Es GA; Juni P; Windecker S
EuroIntervention; 2011 Nov; 7(7):789-95. PubMed ID: 22027687
[TBL] [Abstract][Full Text] [Related]
32. Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial.
Sabate M; Cequier A; Iñiguez A; Serra A; Hernandez-Antolin R; Mainar V; Valgimigli M; Tespili M; den Heijer P; Bethencourt A; Vazquez N; Gómez-Hospital JA; Baz JA; Martin-Yuste V; van Geuns RJ; Alfonso F; Bordes P; Tebaldi M; Masotti M; Silvestro A; Backx B; Brugaletta S; van Es GA; Serruys PW
Lancet; 2012 Oct; 380(9852):1482-90. PubMed ID: 22951305
[TBL] [Abstract][Full Text] [Related]
33. A 10-month angiographic and 4-year clinical outcome of everolimus-eluting versus sirolimus-eluting coronary stents in patients with diabetes mellitus (the DiabeDES IV randomized angiography trial).
Maeng M; Baranauskas A; Christiansen EH; Kaltoft A; Holm NR; Krusell LR; Ravkilde J; Tilsted HH; Thayssen P; Jensen LO
Catheter Cardiovasc Interv; 2015 Dec; 86(7):1161-7. PubMed ID: 25640050
[TBL] [Abstract][Full Text] [Related]
34. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial.
Valgimigli M; Campo G; Percoco G; Bolognese L; Vassanelli C; Colangelo S; de Cesare N; Rodriguez AE; Ferrario M; Moreno R; Piva T; Sheiban I; Pasquetto G; Prati F; Nazzaro MS; Parrinello G; Ferrari R;
JAMA; 2008 Apr; 299(15):1788-99. PubMed ID: 18375998
[TBL] [Abstract][Full Text] [Related]
35. Biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent in patients with acute myocardial infarction.
Lee HJ; Park TK; Song YB; Choi YJ; Yu CW; Yang JH; Hahn JY; Choi SH; Choi RK; Choi JH; Park JS; Kim JS; Kim TH; Jang HJ; Lee SH; Shim WH; Roh YM; Gwon HC
Int J Cardiol; 2015 Mar; 183():190-7. PubMed ID: 25668147
[TBL] [Abstract][Full Text] [Related]
36. Everolimus-eluting stents versus sirolimus- or paclitaxel-eluting stents: two-year results from the Guthrie Health Off-Label Stent (GHOST) registry.
Harjai KJ; Kondareddy S; Pinkosky B; Harjai N; Orshaw P; Boura J
J Interv Cardiol; 2013 Apr; 26(2):153-62. PubMed ID: 23363439
[TBL] [Abstract][Full Text] [Related]
37. Clinical follow-up 3 years after everolimus- and paclitaxel-eluting stents: a pooled analysis from the SPIRIT II (A Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions) and SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Caixeta A; Lansky AJ; Serruys PW; Hermiller JB; Ruygrok P; Onuma Y; Gordon P; Yaqub M; Miquel-Hebert K; Veldhof S; Sood P; Su X; Jonnavithula L; Sudhir K; Stone GW;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1220-8. PubMed ID: 21232715
[TBL] [Abstract][Full Text] [Related]
38. The SPIRIT V study: a clinical evaluation of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions.
Grube E; Chevalier B; Smits P; Džavík V; Patel TM; Mullasari AS; Wöhrle J; Stuteville M; Dorange C; Kaul U;
JACC Cardiovasc Interv; 2011 Feb; 4(2):168-75. PubMed ID: 21349455
[TBL] [Abstract][Full Text] [Related]
39. Clinical impact of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized clinical trials.
Piscione F; Piccolo R; Cassese S; Galasso G; Chiariello M
Catheter Cardiovasc Interv; 2009 Aug; 74(2):323-32. PubMed ID: 19360858
[TBL] [Abstract][Full Text] [Related]
40. Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).
Vlachojannis GJ; Smits PC; Hofma SH; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; den Heijer P; van der Ent M
JACC Cardiovasc Interv; 2017 Jun; 10(12):1215-1221. PubMed ID: 28579236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
